Summary

The global Antibody Drug Conjugate CDMO market size was US$ 3581 million in 2025 and is forecast to reach a readjusted size of US$ 8167 million by 2032 with a CAGR of 12.7% during the forecast period 2026-2032.
Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.
Antibody Drug Conjugates (ADCs) represent one of the fastest-growing and most sophisticated segments in targeted cancer therapy. By combining the precise targeting ability of monoclonal antibodies with the potent cell-killing effect of cytotoxic drugs, ADCs offer a powerful treatment strategy that minimizes harm to healthy tissues.
However, ADCs are among the most complex biologic-drug hybrids to manufacture — they require expertise in biologics production, high-potency active pharmaceutical ingredient (HPAPI) synthesis, advanced conjugation technology, and high-containment fill-finish capabilities.
This is where Contract Development and Manufacturing Organizations (CDMOs) come in. They provide specialized technical infrastructure and know-how for biopharma companies that want to develop and commercialize ADCs without building expensive in-house capacity.
The ADC CDMO market has grown significantly in recent years, fueled by an expanding pipeline of ADCs in clinical trials and rising numbers of commercial approvals. Leading CDMOs now offer end-to-end solutions covering monoclonal antibody production, payload synthesis, conjugation, and sterile, high-containment packaging.
Growing Number of Approved ADCs and Robust Clinical Pipeline
More than a dozen ADCs have received regulatory approval worldwide, with blockbusters like Enhertu®, Padcev®, and Polivy® demonstrating strong commercial success. At the same time, hundreds of new ADCs are in preclinical and clinical development targeting a wide range of cancers and even some non-oncology indications. This expanding pipeline fuels sustained demand for expert CDMO services from early development through to commercial scale-up.
Rising Demand for End-to-End Solutions
Pharma companies increasingly prefer one-stop CDMO partners that can handle the entire ADC value chain — from cell line development to final fill-finish — under a single quality system and contract. This integrated model simplifies supply chains, shortens development timelines, and reduces risk, giving CDMOs with full-spectrum ADC capabilities a competitive edge.
Increased Investment in High-Potency Manufacturing Capacity
As the ADC market expands, leading CDMOs are investing heavily to expand or build new high-containment suites and HPAPI production lines. This growth is critical because HPAPI synthesis and handling require specialized equipment, isolated work areas, and rigorous operator safety systems.
Companies like Lonza, WuXi XDC, Piramal Pharma Solutions, and Sterling Pharma Solutions have made significant capital investments to meet the increasing global demand.
The global Antibody Drug Conjugate CDMO market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
Lonza Group
Porton Pharma Solutions
WuXi XDC
BOC Sciences
Asymchem
Catalent Biologics
3PBIOVIAN
Genscript
AGC Biologics
MabPlex
ChemExpress
Abzena
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
AbbVie Contract Manufacturing
TOT Biopharm
Huadong Medicine
Innovent Biologics
Zhenhao Biology
Porton Pharma Solutions
Segment by Type
Cleavable Linker ADCs
Non-Cleavable Linker ADCs
Segment by Application
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Antibody Drug Conjugate CDMO market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Antibody Drug Conjugate CDMO value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Cleavable Linker ADCs
1.2.3 Non-Cleavable Linker ADCs
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Small and Medium-sized Pharmaceutical Companies
1.3.3 Large Pharmaceutical Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Antibody Drug Conjugate CDMO Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Antibody Drug Conjugate CDMO Market Share by Revenue, by Region (2021-2026)
2.4 Global Antibody Drug Conjugate CDMO Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Antibody Drug Conjugate CDMO Market Size and Prospective (2021-2032)
2.5.2 Europe Antibody Drug Conjugate CDMO Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Antibody Drug Conjugate CDMO Market Size and Prospective (2021-2032)
2.5.4 Latin America Antibody Drug Conjugate CDMO Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Antibody Drug Conjugate CDMO Market Size and Prospective (2021-2032)

3 Breakdown Data by Type
3.1 Global Antibody Drug Conjugate CDMO Historical Market Size by Type (2021-2026)
3.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Antibody Drug Conjugate CDMO

4 Breakdown Data by Application
4.1 Global Antibody Drug Conjugate CDMO Historical Market Size by Application (2021-2026)
4.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Antibody Drug Conjugate CDMO Applications

5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue (2021-2026)
5.1.2 Global Antibody Drug Conjugate CDMO Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Antibody Drug Conjugate CDMO Revenue
5.4 Global Antibody Drug Conjugate CDMO Market Concentration Analysis
5.4.1 Global Antibody Drug Conjugate CDMO Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate CDMO Revenue in 2025
5.5 Global Key Players of Antibody Drug Conjugate CDMO Head Offices and Areas Served
5.6 Global Key Players of Antibody Drug Conjugate CDMO, Product and Application
5.7 Global Key Players of Antibody Drug Conjugate CDMO, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Antibody Drug Conjugate CDMO Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Antibody Drug Conjugate CDMO Market Size by Type (2021-2026)
6.1.2.2 North America Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Antibody Drug Conjugate CDMO Market Size by Application (2021-2026)
6.1.3.2 North America Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
6.1.4 North America Antibody Drug Conjugate CDMO Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Antibody Drug Conjugate CDMO Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Antibody Drug Conjugate CDMO Market Size by Type (2021-2026)
6.2.2.2 Europe Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Antibody Drug Conjugate CDMO Market Size by Application (2021-2026)
6.2.3.2 Europe Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
6.2.4 Europe Antibody Drug Conjugate CDMO Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Antibody Drug Conjugate CDMO Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Antibody Drug Conjugate CDMO Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Antibody Drug Conjugate CDMO Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Antibody Drug Conjugate CDMO Market Size by Type (2021-2026)
6.4.2.2 Latin America Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Antibody Drug Conjugate CDMO Market Size by Application (2021-2026)
6.4.3.2 Latin America Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
6.4.4 Latin America Antibody Drug Conjugate CDMO Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Antibody Drug Conjugate CDMO Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Antibody Drug Conjugate CDMO Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities

7 Key Player Profiles
7.1 Lonza Group
7.1.1 Lonza Group Company Details
7.1.2 Lonza Group Business Overview
7.1.3 Lonza Group Antibody Drug Conjugate CDMO Introduction
7.1.4 Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.1.5 Lonza Group Recent Development
7.2 Porton Pharma Solutions
7.2.1 Porton Pharma Solutions Company Details
7.2.2 Porton Pharma Solutions Business Overview
7.2.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Introduction
7.2.4 Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.2.5 Porton Pharma Solutions Recent Development
7.3 WuXi XDC
7.3.1 WuXi XDC Company Details
7.3.2 WuXi XDC Business Overview
7.3.3 WuXi XDC Antibody Drug Conjugate CDMO Introduction
7.3.4 WuXi XDC Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.3.5 WuXi XDC Recent Development
7.4 BOC Sciences
7.4.1 BOC Sciences Company Details
7.4.2 BOC Sciences Business Overview
7.4.3 BOC Sciences Antibody Drug Conjugate CDMO Introduction
7.4.4 BOC Sciences Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.4.5 BOC Sciences Recent Development
7.5 Asymchem
7.5.1 Asymchem Company Details
7.5.2 Asymchem Business Overview
7.5.3 Asymchem Antibody Drug Conjugate CDMO Introduction
7.5.4 Asymchem Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.5.5 Asymchem Recent Development
7.6 Catalent Biologics
7.6.1 Catalent Biologics Company Details
7.6.2 Catalent Biologics Business Overview
7.6.3 Catalent Biologics Antibody Drug Conjugate CDMO Introduction
7.6.4 Catalent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.6.5 Catalent Biologics Recent Development
7.7 3PBIOVIAN
7.7.1 3PBIOVIAN Company Details
7.7.2 3PBIOVIAN Business Overview
7.7.3 3PBIOVIAN Antibody Drug Conjugate CDMO Introduction
7.7.4 3PBIOVIAN Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.7.5 3PBIOVIAN Recent Development
7.8 Genscript
7.8.1 Genscript Company Details
7.8.2 Genscript Business Overview
7.8.3 Genscript Antibody Drug Conjugate CDMO Introduction
7.8.4 Genscript Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.8.5 Genscript Recent Development
7.9 AGC Biologics
7.9.1 AGC Biologics Company Details
7.9.2 AGC Biologics Business Overview
7.9.3 AGC Biologics Antibody Drug Conjugate CDMO Introduction
7.9.4 AGC Biologics Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.9.5 AGC Biologics Recent Development
7.10 MabPlex
7.10.1 MabPlex Company Details
7.10.2 MabPlex Business Overview
7.10.3 MabPlex Antibody Drug Conjugate CDMO Introduction
7.10.4 MabPlex Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.10.5 MabPlex Recent Development
7.11 ChemExpress
7.11.1 ChemExpress Company Details
7.11.2 ChemExpress Business Overview
7.11.3 ChemExpress Antibody Drug Conjugate CDMO Introduction
7.11.4 ChemExpress Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.11.5 ChemExpress Recent Development
7.12 Abzena
7.12.1 Abzena Company Details
7.12.2 Abzena Business Overview
7.12.3 Abzena Antibody Drug Conjugate CDMO Introduction
7.12.4 Abzena Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.12.5 Abzena Recent Development
7.13 Ajinomoto Bio-Pharma Services
7.13.1 Ajinomoto Bio-Pharma Services Company Details
7.13.2 Ajinomoto Bio-Pharma Services Business Overview
7.13.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Introduction
7.13.4 Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.13.5 Ajinomoto Bio-Pharma Services Recent Development
7.14 BSP Pharmaceuticals
7.14.1 BSP Pharmaceuticals Company Details
7.14.2 BSP Pharmaceuticals Business Overview
7.14.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Introduction
7.14.4 BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.14.5 BSP Pharmaceuticals Recent Development
7.15 AbbVie Contract Manufacturing
7.15.1 AbbVie Contract Manufacturing Company Details
7.15.2 AbbVie Contract Manufacturing Business Overview
7.15.3 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Introduction
7.15.4 AbbVie Contract Manufacturing Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.15.5 AbbVie Contract Manufacturing Recent Development
7.16 TOT Biopharm
7.16.1 TOT Biopharm Company Details
7.16.2 TOT Biopharm Business Overview
7.16.3 TOT Biopharm Antibody Drug Conjugate CDMO Introduction
7.16.4 TOT Biopharm Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.16.5 TOT Biopharm Recent Development
7.17 Huadong Medicine
7.17.1 Huadong Medicine Company Details
7.17.2 Huadong Medicine Business Overview
7.17.3 Huadong Medicine Antibody Drug Conjugate CDMO Introduction
7.17.4 Huadong Medicine Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.17.5 Huadong Medicine Recent Development
7.18 Innovent Biologics
7.18.1 Innovent Biologics Company Details
7.18.2 Innovent Biologics Business Overview
7.18.3 Innovent Biologics Antibody Drug Conjugate CDMO Introduction
7.18.4 Innovent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.18.5 Innovent Biologics Recent Development
7.19 Zhenhao Biology
7.19.1 Zhenhao Biology Company Details
7.19.2 Zhenhao Biology Business Overview
7.19.3 Zhenhao Biology Antibody Drug Conjugate CDMO Introduction
7.19.4 Zhenhao Biology Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.19.5 Zhenhao Biology Recent Development
7.20 Porton Pharma Solutions
7.20.1 Porton Pharma Solutions Company Details
7.20.2 Porton Pharma Solutions Business Overview
7.20.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Introduction
7.20.4 Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2021-2026)
7.20.5 Porton Pharma Solutions Recent Development

8 Antibody Drug Conjugate CDMO Market Dynamics
8.1 Antibody Drug Conjugate CDMO Industry Trends
8.2 Antibody Drug Conjugate CDMO Market Drivers
8.3 Antibody Drug Conjugate CDMO Market Challenges
8.4 Antibody Drug Conjugate CDMO Market Restraints

9 Research Findings and Conclusion

10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Antibody Drug Conjugate CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Antibody Drug Conjugate CDMO Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Antibody Drug Conjugate CDMO Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Antibody Drug Conjugate CDMO Revenue Share by Region (2021-2026)
Table 6. Global Antibody Drug Conjugate CDMO Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Antibody Drug Conjugate CDMO Revenue Share Forecast by Region (2027-2032)
Table 8. Global Antibody Drug Conjugate CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Antibody Drug Conjugate CDMO Market Share by Revenue, by Type (2021-2026)
Table 10. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Antibody Drug Conjugate CDMO Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Antibody Drug Conjugate CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Antibody Drug Conjugate CDMO Market Share by Revenue, by Application (2021-2026)
Table 15. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Antibody Drug Conjugate CDMO Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Antibody Drug Conjugate CDMO Applications
Table 18. Global Antibody Drug Conjugate CDMO Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Antibody Drug Conjugate CDMO Market Share by Players (2021-2026)
Table 20. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2025)
Table 21. Ranking of Global Top Antibody Drug Conjugate CDMO Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Antibody Drug Conjugate CDMO Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Antibody Drug Conjugate CDMO, Headquarters and Area Served
Table 24. Global Key Players of Antibody Drug Conjugate CDMO, Product and Application
Table 25. Global Key Players of Antibody Drug Conjugate CDMO, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Antibody Drug Conjugate CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Antibody Drug Conjugate CDMO Market Share by Revenue, by Company (2021-2026)
Table 29. North America Antibody Drug Conjugate CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Antibody Drug Conjugate CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Antibody Drug Conjugate CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Antibody Drug Conjugate CDMO Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Antibody Drug Conjugate CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Antibody Drug Conjugate CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Antibody Drug Conjugate CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Antibody Drug Conjugate CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Antibody Drug Conjugate CDMO Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Antibody Drug Conjugate CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Antibody Drug Conjugate CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Antibody Drug Conjugate CDMO Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Application (2021-2026) & (US$ Million)
Table 47. Lonza Group Company Details
Table 48. Lonza Group Business Overview
Table 49. Lonza Group Antibody Drug Conjugate CDMO Product
Table 50. Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 51. Lonza Group Recent Development
Table 52. Porton Pharma Solutions Company Details
Table 53. Porton Pharma Solutions Business Overview
Table 54. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product
Table 55. Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 56. Porton Pharma Solutions Recent Development
Table 57. WuXi XDC Company Details
Table 58. WuXi XDC Business Overview
Table 59. WuXi XDC Antibody Drug Conjugate CDMO Product
Table 60. WuXi XDC Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 61. WuXi XDC Recent Development
Table 62. BOC Sciences Company Details
Table 63. BOC Sciences Business Overview
Table 64. BOC Sciences Antibody Drug Conjugate CDMO Product
Table 65. BOC Sciences Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 66. BOC Sciences Recent Development
Table 67. Asymchem Company Details
Table 68. Asymchem Business Overview
Table 69. Asymchem Antibody Drug Conjugate CDMO Product
Table 70. Asymchem Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 71. Asymchem Recent Development
Table 72. Catalent Biologics Company Details
Table 73. Catalent Biologics Business Overview
Table 74. Catalent Biologics Antibody Drug Conjugate CDMO Product
Table 75. Catalent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 76. Catalent Biologics Recent Development
Table 77. 3PBIOVIAN Company Details
Table 78. 3PBIOVIAN Business Overview
Table 79. 3PBIOVIAN Antibody Drug Conjugate CDMO Product
Table 80. 3PBIOVIAN Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 81. 3PBIOVIAN Recent Development
Table 82. Genscript Company Details
Table 83. Genscript Business Overview
Table 84. Genscript Antibody Drug Conjugate CDMO Product
Table 85. Genscript Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 86. Genscript Recent Development
Table 87. AGC Biologics Company Details
Table 88. AGC Biologics Business Overview
Table 89. AGC Biologics Antibody Drug Conjugate CDMO Product
Table 90. AGC Biologics Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 91. AGC Biologics Recent Development
Table 92. MabPlex Company Details
Table 93. MabPlex Business Overview
Table 94. MabPlex Antibody Drug Conjugate CDMO Product
Table 95. MabPlex Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 96. MabPlex Recent Development
Table 97. ChemExpress Company Details
Table 98. ChemExpress Business Overview
Table 99. ChemExpress Antibody Drug Conjugate CDMO Product
Table 100. ChemExpress Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 101. ChemExpress Recent Development
Table 102. Abzena Company Details
Table 103. Abzena Business Overview
Table 104. Abzena Antibody Drug Conjugate CDMO Product
Table 105. Abzena Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 106. Abzena Recent Development
Table 107. Ajinomoto Bio-Pharma Services Company Details
Table 108. Ajinomoto Bio-Pharma Services Business Overview
Table 109. Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product
Table 110. Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 111. Ajinomoto Bio-Pharma Services Recent Development
Table 112. BSP Pharmaceuticals Company Details
Table 113. BSP Pharmaceuticals Business Overview
Table 114. BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product
Table 115. BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 116. BSP Pharmaceuticals Recent Development
Table 117. AbbVie Contract Manufacturing Company Details
Table 118. AbbVie Contract Manufacturing Business Overview
Table 119. AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Product
Table 120. AbbVie Contract Manufacturing Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 121. AbbVie Contract Manufacturing Recent Development
Table 122. TOT Biopharm Company Details
Table 123. TOT Biopharm Business Overview
Table 124. TOT Biopharm Antibody Drug Conjugate CDMO Product
Table 125. TOT Biopharm Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 126. TOT Biopharm Recent Development
Table 127. Huadong Medicine Company Details
Table 128. Huadong Medicine Business Overview
Table 129. Huadong Medicine Antibody Drug Conjugate CDMO Product
Table 130. Huadong Medicine Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 131. Huadong Medicine Recent Development
Table 132. Innovent Biologics Company Details
Table 133. Innovent Biologics Business Overview
Table 134. Innovent Biologics Antibody Drug Conjugate CDMO Product
Table 135. Innovent Biologics Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 136. Innovent Biologics Recent Development
Table 137. Zhenhao Biology Company Details
Table 138. Zhenhao Biology Business Overview
Table 139. Zhenhao Biology Antibody Drug Conjugate CDMO Product
Table 140. Zhenhao Biology Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 141. Zhenhao Biology Recent Development
Table 142. Porton Pharma Solutions Company Details
Table 143. Porton Pharma Solutions Business Overview
Table 144. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product
Table 145. Porton Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2021-2026) & (US$ Million)
Table 146. Porton Pharma Solutions Recent Development
Table 147. Antibody Drug Conjugate CDMO Market Trends
Table 148. Antibody Drug Conjugate CDMO Market Drivers
Table 149. Antibody Drug Conjugate CDMO Market Challenges
Table 150. Antibody Drug Conjugate CDMO Market Restraints
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources

List of Figures
Figure 1. Antibody Drug Conjugate CDMO Product Picture
Figure 2. Global Antibody Drug Conjugate CDMO Market Share by Type: 2025 vs 2032
Figure 3. Cleavable Linker ADCs Features
Figure 4. Non-Cleavable Linker ADCs Features
Figure 5. Global Antibody Drug Conjugate CDMO Market Share by Application: 2025 vs 2032
Figure 6. Small and Medium-sized Pharmaceutical Companies
Figure 7. Large Pharmaceutical Companies
Figure 8. Antibody Drug Conjugate CDMO Report Years Considered
Figure 9. Global Antibody Drug Conjugate CDMO Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 10. Global Antibody Drug Conjugate CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 11. Global Antibody Drug Conjugate CDMO Market Share by Revenue, by Region: 2021 vs 2025
Figure 12. North America Antibody Drug Conjugate CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 13. Europe Antibody Drug Conjugate CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 14. Asia-Pacific Antibody Drug Conjugate CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 15. Latin America Antibody Drug Conjugate CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 16. Middle East & Africa Antibody Drug Conjugate CDMO Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Global Antibody Drug Conjugate CDMO Market Share by Players in 2025
Figure 18. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2025)
Figure 19. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate CDMO Revenue in 2025
Figure 20. North America Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
Figure 21. North America Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
Figure 22. Europe Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
Figure 23. Europe Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
Figure 24. Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
Figure 25. Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
Figure 26. Latin America Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
Figure 27. Latin America Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
Figure 28. Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Type (2021-2026)
Figure 29. Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Application (2021-2026)
Figure 30. Lonza Group Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 31. Porton Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 32. WuXi XDC Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 33. BOC Sciences Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 34. Asymchem Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 35. Catalent Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 36. 3PBIOVIAN Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 37. Genscript Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 38. AGC Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 39. MabPlex Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 40. ChemExpress Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 41. Abzena Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 42. Ajinomoto Bio-Pharma Services Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 43. BSP Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 44. AbbVie Contract Manufacturing Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 45. TOT Biopharm Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 46. Huadong Medicine Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 47. Innovent Biologics Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 48. Zhenhao Biology Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 49. Porton Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2021-2026)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed